PPADS 

PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC₅₀ values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X₁ and P2X₃ receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain^[1][2][3][4].

PPADS (1-100 μM; 1 min) acts as a competitive, partially surmountable antagonist of NAADP (HY-103317)-induced Ca²⁺ release in sea urchin egg homogenate, with an IC₅₀ of 20.6 μM^[2].
PPADS (100 μM) inhibits the transport of NAADP into NIH-3T3 cells, with an inhibition rate of 31.1%^[2].
PPADS (0.01-30,000 nM; 20 min) potently inhibits ATP (HY-B2176)-evoked inward currents at rat P2X₁ and P2X3 receptors expressed in Xenopus laevis oocytes via non-competitive antagonism (partially reversible after washing), with IC₅₀ values of 68.5 nM and 213.6 nM, respectively^[3].
PPADS (1-30 μM; for at least 20 min) concentration-dependently antagonizes the α,β-methylene ATP-induced contraction of rabbit urinary bladder detrusor muscle mediated by P_2x-purinergic receptors^[4].
PPADS (1-30 μM; at least 20 min) concentration-dependently antagonizes purinergic neurogenic contractions of rabbit detrusor muscle^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PPADS (6.25-25 mg/kg, i.p.; once daily; 11 days (chronic); single administration (acute, on day 3 or day 14 post-injury)) dose-dependently reverses neuropathic pain behaviors in CCI mice. The 25 mg/kg dose fully restores physiological nociceptive thresholds, and simultaneously normalizes the abnormal expressions of proinflammatory cytokines, nitric oxide synthase, NF-κB and myelin proteins in peripheral and central pain signaling pathways^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

511.38

C₁₄H₁₄N₃O₁₂PS₂

149017-66-3

O=CC1=C(C(C)=NC(/N=N/C2=CC=C(S(=O)(O)=O)C=C2S(=O)(O)=O)=C1COP(O)(O)=O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Martucci C, et al. The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice. Pain. 2008;137(1):81-95.  [Content Brief]

  [2]. Billington RA, et al. PPADS is a reversible competitive antagonist of the NAADP receptor. Cell Calcium. 2007;41(6):505-511.  [Content Brief]

  [3]. Brown SG, et al. Actions of a Series of PPADS Analogs at P2X1 and P2X3 Receptors. Drug Dev Res. 2001 Aug;53(4):281-291.  [Content Brief]

  [4]. Ziganshin AU, et al. PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol. 1993;110(4):1491-1495.  [Content Brief]